Diet, fatty acids, and regulation of genes important for heart disease

Current Atherosclerosis Reports

Volumn 6, Issue 6, 2004, Pages 432-440

  Vanden Heuvel, John P ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ALITRETINOIN; ANTIDIABETIC AGENT; ARACHIDONIC ACID; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CONJUGATED LINOLEIC ACID; CYCLOOXYGENASE 2; FATTY ACID; HEXANOIC ACID DERIVATIVE; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; LINOLEIC ACID; LIVER X RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTANIC ACID; PIOGLITAZONE; RETINOID X RECEPTOR; RETINOL; ROSIGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; DAIRY PRODUCT; DIABETES MELLITUS; DIET THERAPY; DISEASE SEVERITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FOOD INTAKE; GENE EXPRESSION REGULATION; HEART DISEASE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MEAT; NONHUMAN; OBESITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 9744235043     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-004-0083-9     Document Type: Review

References (85)

1. Renaud S, Lanzmann-Petithory D: Coronary heart disease: dietary links and pathogenesis. Pub Health Nutr 2001, 4 459-474.
2. Hu FB, Willett WC: Optimal diets for prevention of coronary heart disease. JAMA 2002, 288:2569-2578.
3. Belury MA, Nickel KP, Bird CE, Wu Y: Dietary conjugated linoleic acid modulation of phorbol ester skin tumor promotion. Nutr Cancer 1996, 26:149-157.
4. Ip C, Chin SF, Scimeca JA, Pariza MW: Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res 1991, 51:6118-6124.
5. Yang H, Glickman BW, de Boer JG: Sex-specific induction of mutations by PhIP in the kidney of male and female rats and its modulation by conjugated linoleic acid. Environ Mol Mutagen 2002, 40:116-121.
6. Lee KN, Kritchevsky D, Pariza MW. Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis 1994, 108 19-25.
7. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun 1998, 244:678-682.
8. Honkakoski P, Negishi M: Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000, 347 321-337.
9. Weatherman RV, Fletterick RJ, Scanlan TS: Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem 1999, 68 559-581.
10. Kumar R, Thompson EB: The structure of the nuclear hormone receptors. Steroids 1999, 64:310-319.
11. Di Croce L, Okret S, Kersten S, et al.: Steroid and nuclear receptors. Villefranche-sur-Mer, France, May 25-27, 1999. EMBO J 1999, 18:6201-6210.
12. McDonnell DP, Vegeto E, Gleeson MA: Nuclear hormone receptors as targets for new drug discovery. Biotechnology (NY 1993, 11:1256-1261.
13. Wahli W, Martinez E: Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression. FASEB J 1991, 5:2243-2249.
14. Khan SA, Vanden Heuvel JP: Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J Nutr Biochem 2003, 14:554-567.
15. Committee NRN: A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97:161-163.
16. Clarke SD, Jump DB: Polyunsaturated fatty acid regulation of hepatic gene transcription. J Nutr 1996, 126:1105S- 1109S.
17. Francis GA, Fayard E, Picard F, Auwerx J: Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003, 65:261-311.
18. Wahli W: Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly 2002, 132:83-91.
19. Hihi AK, Michalik L, Wahli W: PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002, 59:790-798.
20. Vanden Heuvel JP: Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. J Nutr 1999, 129:575S-580S.
21. Latruffe N, Vamecq J: Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie 1997, 79:81-94.
22. Gelman L, Fruchart JC, Auwerx J: An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999, 55:932-943.
23. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43 527-550.
24. Moya-Camarena SY, Vanden Heuvel JP, Blanchard SG, et al. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha. J Lipid Res 1999, 40 1426-1433.
25. Moya-Camarena SY, Vanden Heuvel JP, Belury MA: Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim Biophys Acta 1999, 1436 331-342.
26. Peters JM, Park Y, Gonzalez FJ, Pariza MW. Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha- null mice. Biochim Biophys Acta 2001, 1533:233-242.
27. Ziouzenkova O, Perrey S, Asatryan L, et al.: Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 2003, 100:2730-2735.
28. Chawla A, Lee CH, Barak Y, et al.: PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci U S A 2003, 100:1268-1273.
29. Cowart LA, Wei S, Hsu MH, et al.: The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 2002, 277:35105-35112.
30. Krey G, Braissant O, Fu LH, et al.: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator- dependent receptor ligand assay. Mol Endocrinol 1997, 11:779-791.
31. Yu K, Bayona W, Kallen CB, et al.: Differential activation of peroxisome proliferator-activated receptors by eicosanoids J Biol Chem 1995, 270:23975-23983.
32. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
33. Barak Y, Nelson MC, Ong ES, et al.: PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595.
34. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1997, 1:235-241.
35. DeGrazia MJ, Thompson J, Vanden Heuvel JP, Peterson BR: Synthesis of a high-affinity fluorescent ligand PPARg ligand for high-throughput fluorescence polarization assays. Bioorgan Medicinal Chem 2003, 11:4325-4332.
36. Yu Y, Correll PH, Vanden Heuvel JP: Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPARgamma-dependent mechanism. Biochim Biophys Acta 2002, 1581:89-99.
37. McIntyre TM, Pontsler AV, Silva AR, et al.: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 2003, 100:131-136.
38. Davies SS, Pontsler AV, Marathe GK, et al.: Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem 2001, 276:16015-16023.
39. Peters JM, Lee SS, Li W, et al.: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000, 20:5119-5128.
40. Brun RP, Tontonoz P, Forman BM, et al.: Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 1996, 10:974-984.
41. Barbier O, Torra IP, Duguay Y, et al.: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22:717-726.
42. Duval C, Chinetti G, Trottein F, et al.: The role of PPARs in atherosclerosis. Trends Mol Med 2002, 8:422-430.
43. Fruchart JC, Staels B, Duriez P: PPARS, metabolic disease and atherosclerosis. Pharmacol Res 2001, 44:345-352.
44. Vosper H, Khoudoli GA, Graham TL, Palmer CN: Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 2002, 95:47-62.
45. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 2000, 405:421-424.
46. Escher P, Wahli W: Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000, 448:121-138.
47. Rocchi S, Auwerx J: Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. Ann Med 1999, 31:342-351.
48. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996, 1302:93-109.
49. Tontonoz P, Hu E, Graves RA, et al.: mPpar gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
50. Tontonoz P, Nagy L, Alvarez JG, et al.: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 1998, 93:241-252.
51. Zhang B, Berger J, Hu E, et al.: Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha Mol Endocrinol 1996, 10:1457-1466.
52. Kubota N, Terauchi Y, Miki H, et al.: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4:597-609.
53. Ricote M, Huang JT, Welch JS, Glass CK: The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. J Leukocyte Biol 1999, 66 733-739.
54. Lehmann JM, Lenhard JM, Oliver BB, et al.: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272:3406-3410.
55. de Urquiza AM, Liu S, Sjoberg M, et al.: Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain Science 2000, 290:2140-2144.
56. Lengqvist J, De Urquiza AM, Bergman AC, et al.: Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand binding domain. Mol Cell Proteomics 2004, In press.
57. Lemotte PK, Keidel S, Apfel CM: Phytanic acid is a retinoid X receptor ligand. Eur J Biochem 1996, 236 328-333.
58. Claudel T, Leibowitz MD, Fievet C, et al.: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A 2001, 98 2610-2615.
59. Kastner P, Grondona JM, Mark M, et al.: Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 1994, 78:987-1003.
60. Lund EG, Menke JG, Sparrow CP: Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:1169-1177.
61. Millatt LJ, Rocher V, Fruchart IC, Staels B: Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim Biophys Acta 2003, 1631:107-118.
62. Ou J, Tu H, Shan B, et al.: Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR Proc Natl Acad Sci U S A 2001, 98:6027-6032.
63. Pawar A, Botolin D, Mangelsdorf DJ, Jump DB: The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression. J Biol Chem 2003, 278:40736-40743.
64. Miyata KS, McCaw SE, Patel HV, et al.: The orphan nuclear hormone receptor LXR alpha interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferatar signaling. J Biol Chem 1996, 271:9189-9192.
65. Laffitte BA, Repa JJ, Joseph SB, et al.: LXRs control lipid-inducible expoession of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 2001, 98 507-512.
66. Joseph SB, Tontonaz P: LXRs: new therapeutic targets in atherosclerosis? Curr Opin Pharmacol 2003, 3:192-197.
67. Jaye M: LXR agonists for the treatment of atherosclerosis Curr Opin Investig Drugs 2003, 4:1053-1058.
68. Joseph SB, McKilligin E, Pei L, et al.: Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002, 99:7604-7609.
69. Chawla A, Barak Y, Nagy L, et al.: PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001, 7:48-52.
70. Peet DJ, Turley SD, Ma W, et al.: Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
71. Alberti S, Schuster G, Parini P, et al.: Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 2001, 107:565-573.
72. Gottlicher M, Demoz A, Svensson D, et al.: Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor. Biochem Pharmacol 1993, 46 2177-2184.
73. Moya-Camarena SY, Van den Heuvel JP, Belury MA: Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim Biophys Acta 1999, 1436 331-342.
74. Kozak KR, Gupta RA, Moody JS, et al.: 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 2002, 277:23278-23286.
75. Van Veldhoven PP, Mannaerts GP, Declercq P, Baes M: Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)?. Cell Signal 2000, 12 475-479.
76. Muga SJ, Thuillier P, Pavone A, et al.: 8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth Differ 2000, 11:447-454.
77. Murakami K, Ide T, Suzuki M, et al.: Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun 1999, 260:609-613.
78. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat [published erraturn appears in Biochem Biophys Res Commun 1998 Jun 29;247(3):911]. Biochem Biophys Res Commun 1998, 244:678-682.
79. Nagy L, Tontonoz P, Alvarez JG, et al.: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229-240.
80. Shappell SB, Gupta RA, Manning S, et al.: 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001, 61:497-503.
81. Wigren J, Surapureddi S, Olsson AG, et al.: Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein. J Endocrinol 2003, 177:207-214.
82. Song C, Hiipakka RA, Liao S: Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 2000, 65:423-427.
83. Song C, Liao S: Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 2000, 141 4180-4184.
84. Janowski BA, Grogan MJ, Jones SA, et al.: Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A 1999, 96:266-271.
85. Kitareewan S, Burka LT, Tomer KB, et al.: Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol Biol Cell 1996, 7:1153-1166.